News | Amorchem

March 22, 2021 SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche Read article

July 17, 2020 Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases Read article

June 4, 2020 New Company to Advance Research into Made-in-Canada Therapy for Patients with Chronic Pain Read article

June 4, 2020 AmorChem invests in a potential treatment for cerebral amyloid angiopathy and Alzheimer’s disease Attacking central nervous system diseases using the neuroprotective effects of the innate immune system Read article

June 3, 2020 AmorChem Invests in the Work of Sidong Huang at McGill University Using a Novel Target to Address a SMARCA4-deficient Rare and Aggressive Form of Ovarian Cancer Read article

May 12, 2020 Consortium Backs Netherton Syndrome Project From Sinai Health Read article

February 24, 2020 AmorChem invests in a new gene therapy approach to help patients with a devastating orphan disease Read article

February 12, 2020 AmorChem invests in novel approach to target Myc-driven cancers Read article

October 17, 2019 Inversago Pharma Strengthens its Board of Directors with the Appointment of Two Industry Experts Read article